Galcanezumab Looks Promising for Treatment-Resistant Migraine Galcanezumab Looks Promising for Treatment-Resistant Migraine
The calcitonin gene-related peptide monoclonal antibody compared favorably to placebo for reducing the number of average monthly migraine days in a study of people with treatment-resistant migraine.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Source Type: news
More News: Brain | Drugs & Pharmacology | Genetics | Headache | Migraine | Neurology | Neurosurgery | Study